You searched for Response to Abatacept in JIA Categories

Abstract Number: 0714 • ACR Convergence 2020
Response to Abatacept in JIA Categories: Results from the PRCSG/PRINTO JIA Abatacept Phase IV Registry
Daniel J Lovell¹, Nikolay Tzaribachev², Esi Morgan³, Gabriele Simonini⁴, Thomas Griffin⁵, Ekaterina Alexeeva⁶, John Bohnsack⁷, Andrew Zeft⁸, Gerd Horneff⁹, Richard Vehe¹⁰, Valda Stanevicha¹¹, Stacey Tarvin¹², Maria Trachana¹³, Adam Huber¹⁴, Daniel Kietz¹⁵, Ilonka Orban¹⁶, Jason Dare¹⁷, Ivan Foeldvari¹⁸, Pierre Quartier¹⁹, Alyssa Dominique²⁰, Tzuyung Douglas Kou²⁰, Robert Wong²⁰, Alberto Martini²¹, Hermine Brunner³ and Nicolino Ruperto²², ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, ³Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Anna Meyer Children's Hospital, Firenze, Italy, ⁵Levine Children's Hospital, Charlotte, NC, ⁶Scientific Center of Children’s Health of RAMS, Moscow, Russia, ⁷University of Utah and Primary Children's Hospital, Cincinnati, OH, ⁸Cleveland Clinic, Cleveland, OH, ⁹Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ¹⁰University of Minnesota, Minneapolis, MN, ¹¹Riga Stradins University, Riga, Latvia, ¹²Riley Children’s Health, Indianapolis, IN, ¹³Aristotle University of Thessaloniki, Thessaloníki, Greece, ¹⁴Dalhousie University, Halifax, NS, Canada, ¹⁵Children’s Hospital of Pittsburgh, Pittsburgh, PA, ¹⁶National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ¹⁷University of Arkansas for Medical Sciences, Little Rock, AR, ¹⁸Hamburg Centre for Pediatric and Adolescent Rheumatology, Hamburg, Germany, ¹⁹Necker-Enfants Malades University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France, ²⁰Bristol-Myers Squibb Company, Princeton, NJ, ²¹PRINTO, Istituto Giannina Gaslini, Genova, Italy, ²²Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: Abatacept, a selective T-cell co-stimulation modulator, has been demonstrated to be well tolerated and effective in JIA in 2 Phase III studies.1,2 The ongoing…
Abstract Number: 0715 • ACR Convergence 2020
JIA-ACR50 Response as a Predictor of Minimal Disease Activity in Patients Aged 2–17 Years with Polyarticular-Course JIA Treated with SC Abatacept
Nicolino Ruperto¹, Hermine I Brunner², Alberto Berman³, Francisco Ávila-Zapata⁴, Gerd Horneff⁵, Maria Alessio⁶, Mara Becker⁷, Alexandre Belot⁸, Ruben Burgos-Vargas⁹, Alina Boteanu¹⁰, Claudia Goldenstein-Schainberg¹¹, Iloite Scheibel¹², Maria Teresa Terreri¹³, Lawrence Zemel¹⁴, Robert Wong¹⁵, Margarita Askelson¹⁵, Marleen Nys¹⁶, Alberto Martini¹⁷ and Daniel J Lovell², ¹Istituto Giannina Gaslini, Genova, Italy, ²PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ³Universidad Nacional de Tucumán and Centro Médico Privado de Reumatología, Tucumán, Argentina, ⁴Star Medica Hospital, Merida, Yucatan, Mexico, ⁵Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ⁶Università di Napoli Federico II, Naples, Italy, ⁷Duke University School of Medicine, Durham, NC, ⁸Centre Hospitalier Universitaire de Lyon, Lyon, France, ⁹Department of Rheumatology, General Hospital of Mexico, Ciudad de Mexico, Mexico, ¹⁰Hospital Universitario Ramón y Cajal, Madrid, Spain, ¹¹University of São Paulo, São Paulo, Brazil, ¹²Hospital Criança Conceição, Porto Alegre, Brazil, ¹³Federal University of São Paulo, São Paulo, Brazil, ¹⁴Connecticut Children’s Medical Center, Hartford, CT, ¹⁵Bristol-Myers Squibb Company, Princeton, NJ, ¹⁶Bristol-Myers Squibb Company, Braine-L’Alleud, Belgium, ¹⁷PRINTO, Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: Effectiveness of SC abatacept in patients with polyarticular-course JIA (pJIA) was shown in a 2-year, open-label Phase III international study (NCT01844518). Here we assess…
Abstract Number: 0106 • ACR Convergence 2026
Immunoproteomic Profiling of Abatacept-treated Patients with Limited Juvenile Idiopathic Arthritis
Lwiza AitDowd¹, Kailey Brodeur², Melanie Kohlheim³, Marc Sudman⁴, Grant Schulert⁴, Eveline Wu⁵, Laura Schanberg⁶, Peter Nigrovic⁷, Laura Berbert⁸, Pui Lee⁹ and Lauren Henderson¹⁰ Affiliations: ¹Boston Children's Hospital, Harvard Medical School, Boston, MA, ²Boston Children's Hospital, Cumberland, RI, ³Self, Granville, OH, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵UNC Chapel Hill, Chapel Hill, NC, ⁶Duke University Medical Center, DURHAM, NC, ⁷Boston Children's Hospital, Brookline, MA, ⁸Boston Children's Hospital, Belmont, MA, ⁹Boston Children's Hospital, Newton, MA, ¹⁰Boston Children's Hospital, Watertown, MA
Background/Purpose: A better understanding of the immune landscape in juvenile idiopathic arthritis (JIA) is needed to develop precision medicine approaches. To address this need, we…
Abstract Number: 0824 • ACR Convergence 2025
Characterizing Immune Responses in Abatacept-treated Patients with Limited Juvenile Idiopathic Arthritis
Lwiza AitDowd¹, Ekaterina Murzin², Alexandra Pommier³, Ki Pui Lam⁴, Claudia Harris⁵, Melanie Kohlheim⁶, Grant Schulert⁷, Marc Sudman⁸, Eveline Wu⁹, Laura Schanberg¹⁰, Peter Nigrovic¹¹, James Lederer¹² and Lauren Henderson¹³, ¹Boston Children's Hospital, Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Harvard Medical School, Boston, MA, ⁴Division of Immunology, Boston Childrens Hospital, Harvard Medical School, Boston, MA, ⁵Division of Immunology, Boston Childrens Hospital, Boston, MA, ⁶CARRA, Granville, OH, ⁷Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Cincinnati Children's Hospital Medical Center, Cincinnati, ⁹UNC Chapel Hill, Chapel Hill, NC, ¹⁰Duke University Medical Center, DURHAM, NC, ¹¹Boston Children's Hospital, Brookline, MA, ¹²Brigham and Women's Hospital, Millis, MA, ¹³Boston Children's Hospital, Watertown, MA
Background/Purpose: Our ability to tailor treatments to individual patients with JIA remains limited. To identify candidate biomarkers that may be associated with treatment response, we…
Abstract Number: 0971 • ACR Convergence 2023
Network Meta Analyses of the Effectiveness and Safety Profiles of Janus Kinase Inhibitors and Biologic Agents in Treating Children with Non-systemic Juvenile Idiopathic Arthritis (nsJIA)
Bin Huang¹, Yuxiang Li², Xiaomeng Yue³, Sandra Andorf², Daniel J Lovell⁴ and Hermine Brunner⁵, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³James L. Winkle College Pharmacy, Cincinnati, OH, ⁴UC Department of Pediatrics, Cincinnati Children's Hospital, University of Cincinnati, Cincinnati, OH, ⁵Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH
Background/Purpose: Tofacitinib (TOFA, NCT02592434) and Baricitinib (BARI, NCT03773978) are Janus kinase inhibitors (JAKi) that are approved for or being tested for nsJIA treatment. We aim…
Abstract Number: 0243 • ACR Convergence 2021
Effectiveness of Abatacept in Patients with JIA, Classified by Category: Results from the PRCSG/PRINTO JIA Real-World Registry
Daniel Lovell¹, Nikolay Tzaribachev², Tracy Ting³, Ekaterina Alexeeva⁴, Teresa Giani⁵, Thomas Griffin⁶, John Bohnsack⁷, Andrew Zeft⁸, Richard Vehe⁹, Stacey Tarvin¹⁰, Gerd Horneff¹¹, Maria Trachana¹², Alyssa Dominique¹³, Lixian Dong¹³, Tzuyung Douglas Kou¹³, Robert Wong¹⁴, Alberto Martini¹⁵, Hermine Brunner³ and Nicolino Ruperto¹⁶, ¹Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, OH, ²PRI Research, Bad Bramstedt, Germany, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Scientific Center of Children Health of RAMS, Moscow, Russia, ⁵Università di Siena, Siena, Italy, ⁶Levine Children's Hospital, Charlotte, NC, ⁷University of Utah, Salt Lake City, UT, ⁸Cleveland Clinic, Cleveland, OH, ⁹University of Minnesota, Twin Cities, MN, ¹⁰Riley Hospital for Children at Indiana University, Indianapolis, IN, ¹¹Paediatric Rheumatology International Trials Organisation (PRINTO), Sankt Augustin, Germany, ¹²Aristotle University of Thessaloniki, Thessaloniki, Greece, ¹³Bristol Myers Squibb, Princeton, NJ, ¹⁴Bristol Myers Squibb, Basking Ridge, NJ, ¹⁵Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ¹⁶IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy
Background/Purpose: Long-term treatment with abatacept, a selective T-cell co-stimulation modulator, is effective and well tolerated in patients with JIA.1–4 The objective of this analysis was…
Abstract Number: 0245 • ACR Convergence 2021
Long-term Safety and Effectiveness of Abatacept Treatment in Patients with JIA: 5-year Results from the PRCSG/PRINTO JIA Real-World Registry
Hermine Brunner¹, Daniel Lovell², Michael Henrickson¹, Ruy Carrassco³, Kirsten Minden⁴, Lyudmila Grebenkina⁵, James Nocton⁶, Ingrid Louw⁷, Linda Wagner-Weiner⁸, Gabriel Vega Cornejo⁹, Sylvia Kamphuis¹⁰, Vyacheslav Chasnyk¹¹, Heather Walters¹², Simone Appenzeller¹³, Jordi Anton¹⁴, Alyssa Dominique¹⁵, Robert Wong¹⁶, Lixian Dong¹⁵, Tzuyung Douglas Kou¹⁵, Alberto Martini¹⁷ and Nicolino Ruperto¹⁸, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, OH, ³Presbyterian Health Services, Albuquerque, NM, ⁴Charite University Hospital Berlin, Berlin, Germany, ⁵Togliatti City Clinical Hospital №5, Togliatti, Russia, ⁶Medical College of Wisconsin, Milwaukee, WI, ⁷Panorama Medical Centre, Cape Town, South Africa, ⁸University of Chicago (Comer Children's), Chicago, IL, ⁹Crea de Guadalajara/Hospital México Americano, Guadalajara, Mexico, ¹⁰Sophia Children’s Hospital, Erasmus University Medical Center, Rotterdam, Netherlands, ¹¹Saint-Petersburg State Pediatric Medical Academy, Saint Petersburg, Russia, ¹²Cohen Children's Hospital, New York, NY, ¹³Hospital das Clínicas da Universidade Estadual de Campinas, Campinas, Brazil, ¹⁴Hospital Sant Joan de Deu, University of Barcelona, Barcelona, Spain, ¹⁵Bristol Myers Squibb, Princeton, NJ, ¹⁶Bristol Myers Squibb, Basking Ridge, NJ, ¹⁷Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ¹⁸IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy
Background/Purpose: Abatacept (ABA) is well tolerated and effective in patients with JIA.1 The Pediatric Rheumatology Collaborative Study Group (PRCSG)/ Paediatric Rheumatology INternational Trials Organisation (PRINTO)…
Abstract Number: 0247 • ACR Convergence 2021
Three-year Effectiveness in Patients with JIA Initiating Abatacept: Results from the PRCSG/PRINTO JIA Real-World Registry
Nicolino Ruperto¹, Hermine Brunner², Nikolay Tzaribachev³, Ilonka Orbán⁴, Valda Staņēviča⁵, Ana Quintero del Rio⁶, Pierre Quartier⁷, Adam Huber⁸, Dan Kietz⁹, Jason Dare¹⁰, Daniel Kingsbury¹¹, T. Brent Graham¹², Ivan Foeldvari¹³, Julisa Patel¹⁴, Alyssa Dominique¹⁵, Lixian Dong¹⁵, Tzuyung Douglas Kou¹⁵, Robert Wong¹⁶, Alberto Martini¹⁷ and Daniel Lovell¹⁸, ¹IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³PRI Research, Bad Bramstedt, Germany, ⁴National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ⁵Riga Stradins University, Riga, Latvia, ⁶Dr. Ramon Ruiz Arnau University Hospital, Bayamόn, PR, ⁷Necker-Enfants Malades University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France, ⁸Dalhousie University, Halifax, NS, Canada, ⁹Children’s Hospital of Pittsburgh, Pittsburg, PA, ¹⁰University of Arkansas for Medical Sciences, Little Rock, AR, ¹¹Randall Children's Hospital at Legacy Emanuel, Portland, OR, ¹²Vanderbilt University Medical Center, Nashville, TN, ¹³Hamburg Centre for Pediatric and Adolescent Rheumatology, Hamburg, Germany, ¹⁴Children’s Hospital of Georgia, Augusta University Medical Center, Augusta, GA, ¹⁵Bristol Myers Squibb, Princeton, NJ, ¹⁶Bristol Myers Squibb, Basking Ridge, NJ, ¹⁷Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ¹⁸Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, OH
Background/Purpose: The ongoing phase 4 Pediatric Rheumatology Collaborative Study Group (PRCSG)/Paediatric Rheumatology INternational Trials Organisation (PRINTO) registry was designed to assess the long-term (up to…
Abstract Number: 1991 • ACR Convergence 2020
Abatacept Treatment Reduces Cutaneous and Joint Activity in Juvenile Localized Scleroderma
Suzanne Li¹, Sarah Ishaq², Mary Buckley³, Kathryn Torok⁴, Barbara Edelheit⁵, Kaleo Ede⁶, Christopher Liu⁷ and C. Egla Rabinovich⁸, ¹Hackensack University Medical Center, Hackensack, ²Montclair State University, Montclair, ³Duke University, Durham, NC, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Conneticut Children's Medical Center, Hartford, ⁶Phoenix Children's Hospital, Phoenix, AZ, ⁷U Pittsburgh, Pittsburgh, ⁸Duke University Hospital, Durham, NC
Background/Purpose: Juvenile localized scleroderma (jLS) is an autoimmune disease commonly associated with damage. Damage includes dyspigmentation, tissue atrophy, arthropathy, hemiatrophy, vision loss, and seizures. To…
Abstract Number: 0733 • ACR Convergence 2020
Practice Patterns for Tapering Medications in the Treatment of JIA-associated Uveitis
Ivan Foeldvari¹, Jens Klotsche², Sheila Angeles-Han³, Jordi Anton⁴, Gabriele Simonini⁵, Nadine Groesch² and Jean Baer⁶, ¹Head of the Hamburg Centre for Pediatric and Adolescence Rheumatology, Budapest, Hungary, ²German Rheumatism Research Center, Berlin, Germany, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Sant Joan de Déu Hospital, Madrid, Spain, ⁵Anna Meyer Children's Hospital, Firenze, Italy, ⁶Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Juvenile idiopathic arthritis associated uveitis (JIAU) is the most common extra-articular manifestation of JIA, and occurs in approximately 10% of affected children. Although there…
Abstract Number: 024 • Pediatric Rheumatology Symposium 2020
Abatacept Treatment Reduces Cutaneous and Joint Activity in Juvenile Localized Scleroderma
Suzanne Li¹, Sarah Ishaq ², Mary Buckley ³, Kathryn Torok ⁴, Barbara Edelheit ⁵, Kaleo Ede ⁶ and C. Egla Rabinovich ⁷, ¹Joseph M. Sanzari Children's Hospital Hackensack Meridian Health, Hackensack, ²Montclair State University, montclair, ³Duke University, Durham, ⁴Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, ⁵CT Children's Medical Center, Hartford, ⁶Phoenix Children's Hospital, Phoenix, ⁷Duke University Hospital, Durham
Background/Purpose: Juvenile localized scleroderma (jLS) is an autoimmune disease commonly associated with damage. Damage includes dyspigmentation, tissue atrophy, arthropathy, hemiatrophy, vision loss, and seizures. To…
Abstract Number: 2708 • ACR/ARP Annual Meeting 2019
Effect of Immunogenicity on Efficacy and Safety of Subcutaneous or Intravenous Abatacept in Pediatric Patients with Polyarticular-Course JIA: Findings from Two Phase III Trials
Hermine Brunner¹, Nikolay Tzaribachev ², Ingrid Louw ³, Alberto Berman ⁴, Inmaculada Calvo Penadés ⁵, Jordi Antón ⁶, Francisco Ávila-Zapata ⁷, Rubèn J Cuttica ⁸, Gerd Horneff ⁹, Robert Wong ¹⁰, Mehmooda Shaikh ¹¹, Johanna Mora ¹¹, Marleen Nys ¹², Daniel J. Lovell ¹³, Alberto Martini ¹⁴ and Nicolino Ruperto ¹⁵, ¹Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, ³Panorama Medical Centre, Parow, South Africa, ⁴Universidad Nacional de Tucuman and Centro Médico Privado de Reumatología, Tucuman, Argentina, ⁵Hospital Univ. La Fe, Valencia, Spain, ⁶Hospital Sant Joan de Déu, Barcelona, Spain, ⁷Star Medica Hospital, Merida, Yucatán, Mexico, ⁸Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina, ⁹Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ¹⁰Bristol-Myers Squibb, Princeton, ¹¹Bristol-Myers Squibb, Princeton, NJ, ¹²Bristol-Myers Squibb, Braine L’Alleud, Belgium, ¹³Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, ¹⁴IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy, ¹⁵Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy
Background/Purpose: Patients (pts) with polyarticular-course JIA (pJIA) may develop anti-drug antibodies (ADAs) in response to biologics.1 Presence of ADAs has been associated with treatment (tmt)…
Abstract Number: 1815 • ACR/ARP Annual Meeting 2019
Subcutaneous or Intravenous Abatacept Monotherapy in Pediatric Patients with Polyarticular-Course JIA: Results from Two Phase III Trials
Nicolino Ruperto¹, Daniel J. Lovell ², John Bohnsack ³, Johannes Breedt ⁴, Michel Fischbach ⁵, Thomas Lutz ⁶, Kirsten Minden ⁷, Tatiana Miraval ⁸, Mahmood M. T. M. Ally ⁹, Nadina Rubio-Pérez ¹⁰, Elisabeth Gervais ¹¹, Riana van Zyl ¹², Robert Wong ¹³, Marleen Nys ¹⁴, Alberto Martini ¹⁵ and Hermine Brunner ¹⁶, ¹Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ²Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, ³University of Utah School of Medicine, Salt Lake City, UT, ⁴Steve Biko Academic Hospital, University of Pretoria, Pretoria, South Africa, ⁵Pédiatrie 1, CHU Hautepierre, Strasbourg, France, ⁶Heidelberg University Hospital, Heidelberg, Germany, ⁷German Rheumatism Research Center and Charité University Medicine, Berlin, Germany, ⁸Clínica San Gabriel, Lima, Peru, ⁹University of Pretoria, Pretoria, South Africa, ¹⁰University Hospital Dr. José Eleuterio González, Monterrey, Mexico, ¹¹CHU de Poitiers, Rheumatology, Poitiers, France, ¹²University of the Free State, Bloemfontein, South Africa, ¹³Bristol-Myers Squibb, Princeton, ¹⁴Bristol-Myers Squibb, Braine L’Alleud, Belgium, ¹⁵IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy, ¹⁶Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: In EU, abatacept (ABA) with MTX is approved in patients (pts) with polyarticular-course JIA (pJIA), as young as 2 years (SC) and 6 years…
Abstract Number: 1424 • ACR/ARP Annual Meeting 2019
The Effect of HLA-DRB1 Risk Alleles (Shared Epitope) on Changes in Immune Cell Subsets and Disease Activity Following Treatment with Abatacept versus Adalimumab in Seropositive Biologic-Naïve Patients with Early, Moderate-to-Severe RA: Data from a Head-to-Head Single-Blinded Trial
Jane Buckner¹, Vivian Bykerk ², V. Michael Holers ³, S. Louis Bridges ⁴, William Rigby ⁵, Sheng Gao ⁶, Marleen Nys ⁷ and Neelanjana Ray ⁸, ¹Benaroya Research Institute, Seattle, WA, ²Hospital for Special Surgery, New York City, NY, ³University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver, ⁴University of Alabama at Birmingham, Birmingham, ⁵Dartmouth-Hitchcock Medical Center, Lebanon, ⁶Bristol-Myers Squibb, Princeton, NJ, ⁷Bristol-Myers Squibb, Braine L’Alleud, Belgium, ⁸Bristol-Myers Squibb, Princeton
Background/Purpose: Mechanistic differences between biologic DMARDs are poorly understood. Exploring these mechanisms includes assessing the role of HLA-DRB1 alleles containing the shared epitope (SE), which…
Abstract Number: 2378 • ACR/ARHP Annual Meeting 2018
Subcutaneous Abatacept in Patients Aged 2–17 Years with Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Results over 24 Months By Juvenile Idiopathic Arthritis Disease Category
Nicola Ruperto¹, Hermine I. Brunner², Gabriel Vega-Cornejo³, Alberto Berman⁴, Rubén J. Cuttica⁵, Francisco Ávila-Zapata⁶, Michael Henrickson⁷, Daniel J Kingsbury⁸, John F. Bohnsack⁹, Thomas Lutz¹⁰, Nadina E Rubio-Pérez¹¹, Valeria Gerloni¹², Xiaohui Li¹³, Marleen Nys¹⁴, Robert Wong¹³, Alberto Martini¹⁵ and Daniel J Lovell¹⁶, ¹Istituto Giannina Gaslini - Clinica Pediatrica e Reumatologia, Genoa, Italy, ²Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Clinica de Reumatología y Enfermedades Autoinmunes (CREA), Hospital México Americano, Guadalajara Jalisco, Mexico, ⁴Centro Médico Privado de Reumatología, Tucumán, Argentina, ⁵Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina, ⁶Star Medica Hospital, Merida, Yucatán, Mexico, ⁷Cincinnati Children’s Medical Center, Cincinnati, OH, ⁸Randall Children’s Hospital at Legacy Emanuel, Portland, OR, ⁹University of Utah School of Medicine, Salt Lake City, UT, ¹⁰Pediatric Rheumatology, University Hospital, Center for Pediatric and Adolescent Medicine / Clinic 1, Heidelberg, Germany, ¹¹Universidad Autónoma de Nuevo León, Monterrey Nuevo León, Mexico, ¹²Istituto Gaetano Pini, Milan, Italy, ¹³Bristol-Myers Squibb, Princeton, NJ, ¹⁴Bristol-Myers Squibb, Braine L’Alleud, Belgium, ¹⁵Istituto G. Gaslini Pediatria II Reumatologia and University of Genova, Genova, Italy, ¹⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: The effect of biologic DMARDs on different juvenile idiopathic arthritis (JIA) categories is poorly understood. In patients (pts) with JIA aged 2–17 years (y),…

Search Results